期刊
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
卷 47, 期 7, 页码 624-630出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/0004867412470010
关键词
Early; first episode; long-acting antipsychotic injections; schizophrenia
类别
资金
- Janssen
Background: The relapse rate after a first episode of schizophrenia is high, often due to non-adherence with medication. Long-acting injections of antipsychotics (LAI) are used to promote adherence to medication. Objective: To review the literature on the use of LAIs in first-episode and early schizophrenia. Method: A systematic electronic search of all original data containing peer-reviewed studies published in English using EMBASE, MEDLINE, Cochrane and PsychINFO from the onset of records. Reference lists from retrieved articles were examined for further relevant studies. Results: Ten studies were identified: two cohort studies; three randomised controlled trials; and five open studies. These studies, although limited, demonstrated the effectiveness of LAI in early schizophrenia. Seven of the 10 studies had risperidone long-acting injection as the only LAI. Conclusion: LAIs may be useful in the treatment of early schizophrenia in terms of symptom control and relapse reduction, particularly if chosen by the patient or when medication adherence is a priority. There is a need for a large-scale, randomised controlled trial comparing oral and LAI antipsychotics to assess long-term outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据